Endotrophin Levels Could Predict Kidney Disease Outcomes in Type 2 Diabetes


Alexandra Louise Møller, MS, PhD, discusses the results of a PROVALID analysis examining the predictive value of endotrophin levels for predicting CKD events.

An analysis of data from the PROVALID study suggests endotrophin could serve as an early marker of negative kidney outcomes in people with type 2 diabetes.

Presented by Alexandra Louise Møller, MS, PhD, of Nordic Biosciences A/S, at the 61st European Renal Association Congress, results of the study suggest patients with type 2 diabetes and elevated endotrophin levels were at a nearly 70% greater risk of experiencing a negative kidney outcome compared to their counterparts without elevated endotrophin levels.1

A prospective, multinational, non-interventional cohort study, PROVALID collected information related to medical history, physical status, laboratory measurements, and medication use among more than 4000 patients with type 2 diabetes from 5 European countries with the intent of providing clinicians with a database for validating biomarkers. Using data collected in the study, investigator designed the current analysis to assess the association between endotrophin levels and the primary outcome of interest, which was a composite kidney endpoint defined as a sustained 40% decline in eGFR, an eGFR of less than 60 ml/min/173 m2, sustained 30% increase in albuminuria including a transition in albuminuria stage, or kidney failure with replacement therapy or kidney death.1,2

From the PROVALID study, investigators obtained information from a cohort of 3226 individuals with levels of endotrophin measured in plasma at baseline. This cohere had a median age of 64 (58 to 70) years, 57% were males, the mean eGFR was 79 (SD, 24) mL/Min/1.73m2, and the median follow-up time was 3.9 years.1

Upon analysis, results indicated elevated levels of endotrophin were associated with an elevated risk of experiencing a primary outcome event (HR, 1.63; P = .0012). Upon adjustment for age, diabetes duration, HbA1c, atherosclerotic cardiovascular disease, blood pressure, BMI, lipid profile, and eGFR, this increased risk was still present (HR, 1.55; P = .012). In a subgroup analysis among patients with an eGFR greater than 90 mL/min/1.73m2, results suggested elevated endotrophin levels were associated with increased risk of experiencing a primary outcome event (P = .03).1

To learn more about the study and its results, check out our interview with Møller from the floor at ERA 24.

Møller has no relevant disclosures of interest to share.


  1. Møller AL, Thöni S, Keller F, et al. #755 Endotrophin as an early marker of kidney outcomes in persons with type 2 diabetes: findings from the PROVALID study. Nephrology Dialysis Transplantation. Volume 39, Issue Supplement_1. May 2024. https://doi.org/10.1093/ndt/gfae069.528
  2. Eder S, Leierer J, Kerschbaum J, et al. A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) - Study Design and Baseline Characteristics. Kidney Blood Press Res. 2018;43(1):181-190. doi:10.1159/000487500
Related Videos
Ghada Bourjeily, MD: Research Gaps on Sleep Issues During Pregnancy
John Winkelman, MD, PhD: When to Use Low-Dose Opioids for Restless Legs Syndrome
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Jennifer Martin, PhD: Boosting CPAP Adherence in Women with Sleep Apnea
Video 2 -  4 KOLs are featured in, "Educating Primary Care Clinicians on Outpatient HE Management and Ammonia Testing"
Video 1 - 4 KOLs are featured in, "Exploring the Impact of Hepatic Encephalopathy on Patients and Their Families "
© 2024 MJH Life Sciences

All rights reserved.